Background: There is an amenable need for clinically applicable biomarkers in patients with SARS-CoV-2 infection. Red Cell Distribution Width (RDW) has been recently suggested as a prognostic biomarker for COVID-19. Methods: This was an observational study enrolling patients between February 26 and May 15 2020. We aimed to validate the association of the previously published RDW threshold of 14.5% with markers of disease progression and mortality. Results: A total number of 193 hospitalized patients with COVID-19 were enrolled and analyzed. Median age was 61 years (95% CI: 58–64). Patients with baseline RDW ≥14.5% ( n = 41, 19.2%) presented with more progressive disease compared to patients with baseline RDW <14.5% ( n = 156, 80.8%) as indicated by significant differences in maximum FiO2% during hospitalization (median: 100, 95% CI: 45.2–100, vs. 35, 95% CI: 31–40, p = 0.0001, respectively). Values of RDW ≥14.5% were also strongly associated with increased risk of mortality (HR: 4.1, 95% CI: 0.88–19.23), ( p = 0.02). Conclusion: Our study provides evidence to support reproducibility and validity of a specified cut-off threshold of RDW as biomarker of disease severity and mortality in patients with COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, Biomarkers, Mortality, Red cell distribution width (RDW), 【초록키워드】 Biomarker, Hospitalization, disease severity, Infection, Disease progression, Patient, Validity, age, threshold, prognostic biomarker, association, marker, Evidence, Support, significant difference, increased risk, width, progressive disease, reproducibility, cut-off threshold, value, enrolled, analyzed, indicated, clinically, provide, hospitalized patient, suggested, baseline, patients with COVID-19, patients with SARS-CoV-2, Red, with COVID-19, 【제목키워드】 width, Increased, Red,